Cliff Elcombe

TL;DR: Evidence is provided that hESCs can be differentiated efficiently in vitro to functional hepatocytes, which may be useful as an in vitro system for toxicity screening in drug discovery and evidence that the hESC‐derived hepatocytes are able to carry out a range of hepatocyte functions.

TL;DR: It is suggested that lowering of serum total cholesterol may not be the earliest clinically-measurable response to treatment in the rat and it is confirmed that serum and liver PFOS concentrations on repeated dosing are proportional to dose and cumulative dose.

TL;DR: The hepatocarcinogenic response of rodents to DEHP is not relevant to human cancer risk at any anticipated exposure level, and DEHP should be classified an unlikely human carcinogen with a margin of exposure (MOE) approach to risk assessment.

TL;DR: There were no APFO-related macroscopic or microscopic changes, changes in clinical chemistry, hormones, or urinalysis, or hematological effects, and effects that have been associated with the development of pancreatic and testicular toxicity in rats were not observed in this study.

TL;DR: Consensus was reached regarding the significant intermediary roles of cell proliferation and PPAR-alpha receptor expression and activation in tumor formation and risk assessments based on tumor data may not be appropriate.